AbbVie (NYSE:ABBV) announces positive results from a Phase 3 clinical trial, SELECT-PsA 1, evaluating RINVOQ (upadacitinib) in adults with psoriatic arthritis (PA) who failed to respond adequately to or were intolerant of DMARD (disease modifying anti-rheumatic drug) therapy.
AbbVie (NYSE:ABBV) announces positive results from a Phase 3 clinical trial, SELECT-PsA 1, evaluating RINVOQ (upadacitinib) in adults with psoriatic arthritis (PA) who failed to respond adequately to or were intolerant of DMARD (disease modifying anti-rheumatic drug) therapy.
やりましたね！！